價格 |
包裝 |
發(fā)貨地 | 福建 |
更新日期 | 2015-12-05 |
中文名稱:VR23 | 英文名稱:Quinoline, 7-?chloro-?4-?[4-?[(2,?4-?dinitrophenyl)?sulfonyl]?-?1-?piperazinyl]?- |
CAS:1624602-30-7 | 有效期: 三個月 |
VR23有效抑制胰蛋白酶樣蛋白酶 (IC50=1nM), 胰凝乳蛋白酶樣蛋白酶 (IC50 =50-100 nM), 和caspase樣蛋白酶 (IC50 =3μM)。
VR23 is a small molecule that potently inhibited the activities of trypsin-like proteasomes (IC50 = 1 nM), chymotrypsin-like proteasomes (IC50 = 50-100 nM), and caspase-like proteasomes (IC50 = 3 μM).
IC50 value: 1 nM (trypsin-like proteasome), 50-100 nM(chymotrypsin-like proteasome), 3 μM (caspase-like proteasome)
Target: proteasome
in vitro: VR23 is a novel proteasome inhibitor targeting β2 of the 20S proteasome subunit. VR23 produces a synergistic effect in killing multiple myeloma cells, including those that were resistant to bortezomib. VR23 as a structurally novel proteasome inhibitor with desirable properties as an anticancer agent.
in vivo: VR23 shows effective antitumor and antiangiogenic activities in mice.
成立日期 | 2012-12-11 (13年) | 注冊資本 | 200萬人民幣 |
員工人數(shù) | 年營業(yè)額 | ||
主營行業(yè) | 中間體,醫(yī)藥原料 | 經(jīng)營模式 | 試劑,定制 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥2300.00 |
VIP9年
|
北京索萊寶科技有限公司
|
2025-01-23 | |
¥123 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-12 | |
¥498.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |